| Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk P Urban, R Mehran, R Colleran, DJ Angiolillo, RA Byrne, D Capodanno, ... Circulation 140 (3), 240-261, 2019 | 929 | 2019 |
| 2017 cardiovascular and stroke endpoint definitions for clinical trials KA Hicks, KW Mahaffey, R Mehran, SE Nissen, SD Wiviott, B Dunn, ... Circulation 137 (9), 961-972, 2018 | 669 | 2018 |
| Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium PT Sager, G Gintant, JR Turner, S Pettit, N Stockbridge American heart journal 167 (3), 292-300, 2014 | 570 | 2014 |
| Developing therapies for heart failure with preserved ejection fraction: current state and future directions J Butler, GC Fonarow, MR Zile, CS Lam, L Roessig, EB Schelbert, ... JACC: Heart Failure 2 (2), 97-112, 2014 | 472 | 2014 |
| Evolution of strategies to improve preclinical cardiac safety testing G Gintant, PT Sager, N Stockbridge Nature reviews Drug discovery 15 (7), 457-471, 2016 | 404 | 2016 |
| The comprehensive in vitro proarrhythmia assay (CiPA) initiative—update on progress T Colatsky, B Fermini, G Gintant, JB Pierson, P Sager, Y Sekino, ... Journal of pharmacological and toxicological methods 81, 15-20, 2016 | 399 | 2016 |
| International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment K Blinova, Q Dang, D Millard, G Smith, J Pierson, L Guo, M Brock, HR Lu, ... Cell reports 24 (13), 3582-3592, 2018 | 305 | 2018 |
| Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies J Coresh, HJL Heerspink, Y Sang, K Matsushita, J Arnlov, BC Astor, ... The lancet Diabetes & endocrinology 7 (2), 115-127, 2019 | 281 | 2019 |
| Comprehensive translational assessment of human-induced pluripotent stem cell derived cardiomyocytes for evaluating drug-induced arrhythmias K Blinova, J Stohlman, J Vicente, D Chan, L Johannesen, ... Toxicological Sciences 155 (1), 234-247, 2017 | 252 | 2017 |
| Concentration‐QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review CE Garnett, N Beasley, VA Bhattaram, PR Jadhav, R Madabushi, ... The Journal of Clinical Pharmacology 48 (1), 13-18, 2008 | 250 | 2008 |
| Differentiating drug‐induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil L Johannesen, J Vicente, JW Mason, C Sanabria, K Waite‐Labott, ... Clinical Pharmacology & Therapeutics 96 (5), 549-558, 2014 | 244 | 2014 |
| Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document F Zannad, AA Garcia, SD Anker, PW Armstrong, G Calvo, JGF Cleland, ... European journal of heart failure 15 (10), 1082-1094, 2013 | 230 | 2013 |
| Cardiovascular drug development: is it dead or just hibernating? CB Fordyce, MT Roe, T Ahmad, P Libby, JS Borer, WR Hiatt, MR Bristow, ... Journal of the American College of Cardiology 65 (15), 1567-1582, 2015 | 214 | 2015 |
| Clinical trial design and new therapies for pulmonary arterial hypertension O Sitbon, M Gomberg-Maitland, J Granton, MI Lewis, SC Mathai, ... European Respiratory Journal 53 (1), 2019 | 196 | 2019 |
| Results from the IQ‐CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase B Darpo, C Benson, C Dota, G Ferber, C Garnett, CL Green, V Jarugula, ... Clinical Pharmacology & Therapeutics 97 (4), 326-335, 2015 | 177 | 2015 |
| Dealing with global safety issues: was the response to QT-liability of non-cardiac drugs well coordinated? N Stockbridge, J Morganroth, RR Shah, C Garnett Drug safety 36, 167-182, 2013 | 172 | 2013 |
| New trial designs and potential therapies for pulmonary artery hypertension M Gomberg-Maitland, TM Bull, R Saggar, RJ Barst, A Elgazayerly, ... Journal of the American College of Cardiology 62 (25S), D82-D91, 2013 | 166 | 2013 |
| Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative JP Piccini, DJ Whellan, BR Berridge, JK Finkle, SD Pettit, N Stockbridge, ... American heart journal 158 (3), 317-326, 2009 | 142 | 2009 |
| Late sodium current block for drug‐induced long QT syndrome: results from a prospective clinical trial L Johannesen, J Vicente, JW Mason, C Erato, C Sanabria, K Waite‐Labott, ... Clinical Pharmacology & Therapeutics 99 (2), 214-223, 2016 | 140 | 2016 |
| Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil J Vicente, L Johannesen, JW Mason, WJ Crumb, E Pueyo, N Stockbridge, ... Journal of the American Heart Association 4 (4), e001615, 2015 | 137 | 2015 |
